Compare MiniMed Group Inc. Common Stock (MMED) vs Somnigroup International Inc. Common Stock (SGI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MiniMed Group Inc. Common Stock vs Somnigroup International Inc. Common Stock — how do they compare? MiniMed Group Inc. Common Stock trades at $16.74 (market cap $5.18B), while Somnigroup International Inc. Common Stock trades at $62.83 (market cap $14.48B). The key difference: Somnigroup International Inc. Common Stock is far larger — about 2.8× MiniMed Group Inc. Common Stock's market cap, and Somnigroup International Inc. Common Stock pays a 1.08% dividend while MiniMed Group Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold MiniMed Group Inc. Common Stock for 6 Days and Somnigroup International Inc. Common Stock for 0 Days on average.
| MMED | SGI | |
|---|---|---|
Market Cap | $5.18B | $14.48B |
Volume | 33,606,669 | 1,734,399 |
Sector | Health | Consumer Cyclical |
52-Week High | $23.84 | $97.99 |
52-Week Low | $10.80 | $61.49 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $4.98B | $20.78B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MMED trades at $18.40, down 2.13% today, with technical indicators showing bearish momentum. The company reported revenue growth to $2.72B in 2025 but posted a net loss of -$250M. Recent news highlights Medtronic's exchange offer completion and MiniMed's new product launches. Analyst consensus remains strongly bullish with 100% buy ratings and a $25.73 price target, representing 40% upside potential from current levels.
Despite negative profitability metrics and bearish technical signals, MMED maintains strong analyst support and revenue growth trajectory. Key risks include persistent net losses, high short interest, and execution challenges in the competitive diabetes technology market. The stock offers potential upside if new product cycles drive margin improvement and profitability.
Somnigroup International (SGI) trades at $62.87, up 0.75% with neutral technical signals. The company shows strong profitability with 44.24% gross margins and has beaten earnings estimates for three consecutive quarters. Recent acquisition of Leggett & Platt enhances vertical integration with $75M synergy target. Analyst consensus is strongly bullish with 91% buy ratings and $94.50 price target, representing 50% upside potential from current levels.
SGI presents compelling growth prospects through strategic acquisitions and operational efficiencies, though faces margin pressures in weak bedding markets. The stock trades at reasonable valuations (P/E 24.85) with improving cash flow trends expected in 2026. Key risks include integration execution and market competition, but strong institutional interest and insider buying support the bullish case.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MiniMed Group Inc. Common Stock
MiniMed develops, manufactures, and markets diabetes-management technologies. Its products include insulin-delivery systems, continuous glucose monitors, smart insulin pens, and related software.
Read more on MMED →About Somnigroup International Inc. Common Stock
Somnigroup International Inc. (formerly Tempur Sealy International) is a bedding and sleep-products company that designs, manufactures, distributes, and retails mattresses and related products. It operates through Tempur Sealy North America, Tempur Sealy International, and Mattress Firm, with brands including Tempur-Pedic, Sealy, Stearns & Foster, and Mattress Firm.
Read more on SGI →
